Clamp AR, James EC, McNeish IA, et al. - In this phase 3 trial of 1,566 females with newly diagnosed International Federation of Gynecology and Obstetrics stage IC–IV epithelial ovarian cancer, experts contrasted efficiency and safety of two dose-dense weekly regimens to standard 3-weekly chemotherapy in a predominantly European population with epithelial ovarian cancer. No notable progression-free survival rise was recognized with either a weekly regimen. However grade 3 or 4 toxic influences rose with weekly treatment, these impacts were predominantly uncomplicated. Febrile neutropenia and sensory neuropathy incidences were comparable across groups. It was discovered that weekly dose-dense chemotherapy could be provided successfully as first-line treatment for epithelial ovarian cancer, however, in comparison with standard 3-weekly chemotherapy in predominantly European populations, it does not notably enhance progression-free survival.